Pioglitazone (Synonyms: U 72107)

Name: Pioglitazone
Brand: MedChemExpress
SKU: HY-13956
Rating: 5.0 (47 reviews)

Cat. No.: HY-13956 Purity: 99.70%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research.

For research use only. We do not sell to patients.

CAS No. : 111025-46-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 47 publication(s) in Google Scholar

Other Forms of Pioglitazone:

47 Publications Citing Use of MCE Pioglitazone

In Vivo Efficacy Study

Histological Imaging/Staining

RT-PCR

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 10;16(1):8215. [Abstract]; Western blot for NECTIN4 and HPGD in RT112 cells treated with T0070907, Rosiglitazone, and Pioglitazone (1 μM, 72 h).

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 25:e2407134. [Abstract]; Decreased expression of collagen I in activated fibroblasts was consistently shown through immunofluorescence staining after administering 3PO and Pioglitazone (10, 20, 30 μM).

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]; Experimental timelines for behavioral testing following Pioglitazone (15-30 mg/kg, p.o.) treatment. Typical heat plot , social interaction ratio, time in interaction zone.

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Dec 25:e2407134. [Abstract]; Histopathological analysis of mouse lung tissue revealed that treatment with Pioglitazone (10, 20, 30 μM) partially mitigated lung fibrosis, although collagen deposits persisted.

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 11:e08957. [Abstract]; The mRNA expression of inflammatory cytokines Il1b and Il6 decreased in the mPFC from control‐GFP, SUS‐GFP, control‐Pioglitazone and SUS‐Pioglitazone (15-30 mg/kg, p.o.) mice.

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9. [Abstract]; Crypts isolated from Lgr5-EGFP-IRES-creERT2 mice were cultured with CA together with/without 100 μM WY14643/ 10 μM Pioglitazone/ 1 μM GW501516 for 6 days. Representative staining pattern of Lgr5⁺ cells.

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Inflammation. 2020 Apr;43(2):568-578. [Abstract]; Colonic lysates of CON + Veh, DSS + Veh, and DSS + PIO (day 7, day 14, and day 21) group mice are analyzed by immunoblotting with IL-6, TNF-α, MMP9, and PPARγ antibodies, respectively. Each lane represents one mouse.

: Pioglitazone purchased from MedChemExpress. Usage Cited in: Inflammation. 2020 Apr;43(2):568-578. [Abstract]; Colonic lysates of CON + Veh, DSS + Veh, and DSS + PIO (day 7, day 14, and day 21) group mice are analyzed by immunoblotting with p-ERK, ERK, p-P65, and P65 antibodies, respectively. Each lane represents one mouse.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

hPPARγ

0.93 μM (EC₅₀)

mouse PPARγ

0.99 μM (EC₅₀)

hPPARδ

43 μM (EC₅₀)

hPPARα

100 μM (EC₅₀)

mouse PPARα

100 μM (EC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.14 3 Compound: Pioglitazone	Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay	[PMID: 20656494]
CHO	EC₅₀	0.14 3 Compound: Pioglitazone	Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay	[PMID: 20656494]
CHO	EC₅₀	0.39 3 Compound: Pioglitazone	Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay	[PMID: 21377875]
CHO	EC₅₀	0.39 3 Compound: Pioglitazone	Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay	[PMID: 21377875]
COS-1	EC₅₀	0.39 3 Compound: 2	Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay	[PMID: 21130649]
COS-1	EC₅₀	0.39 3 Compound: 2	Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay	[PMID: 21130649]
COS-7	EC₅₀	0.3 3 Compound: Pioglitazone	Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay	[PMID: 21873070]
COS-7	EC₅₀	0.2 3 Compound: Pioglitazone	Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay	[PMID: 26595749]
COS-7	EC₅₀	0.2 3 Compound: pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay	[PMID: 23130964]
COS-7	EC₅₀	0.32 3 Compound: Pioglitazone	Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay	[PMID: 27569195]
COS-7	EC₅₀	0.5 3 Compound: Pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay	[PMID: 27560282]
COS-7	EC₅₀	0.3 3 Compound: Pioglitazone	Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay	[PMID: 21873070]
COS-7	EC₅₀	0.2 3 Compound: pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay	[PMID: 23130964]
COS-7	EC₅₀	0.3 3 Compound: pioglitazone	Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay	[PMID: 20307981]
COS-7	EC₅₀	0.32 3 Compound: Pioglitazone	Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay	[PMID: 27569195]
COS-7	EC₅₀	0.2 3 Compound: Pioglitazone	Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay	[PMID: 26595749]
3T3-L1	EC₅₀	1.6 x 10^-7 41 Compound: pioglitazone	Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells	[PMID: 9599241]
COS-7	EC₅₀	0.3 3 Compound: pioglitazone	Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay	[PMID: 20307981]
COS-7	EC₅₀	0.5 3 Compound: Pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay	[PMID: 27560282]
CV-1	EC₅₀	0.69 3 Compound: 5	In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells	[PMID: 8576907]
CV-1	EC₅₀	580 1 Compound: Pioglitazone	Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.	[PMID: 11720854]
HEK293	EC₅₀	0.21 3 Compound: Pioglitazone	Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay	[PMID: 25333853]
CV-1	EC₅₀	0.55 3 Compound: pioglitazone	Transactivation of PPARgamma in CV1 cells Transactivation of PPARgamma in CV1 cells	[PMID: 16821769]
CHO	EC₅₀	0.14 3 Compound: Pioglitazone	Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay Activation of Gal4-tagged human PPARgamma expressed in CHO cells by luciferase reporter gene assay	[PMID: 20656494]
HEK293	EC₅₀	0.21 3 Compound: Pioglitazone	Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay	[PMID: 25333853]
HEK293	EC₅₀	0.8 3 Compound: 4	Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay	[PMID: 23102891]
HEK293	EC₅₀	1.1 3 Compound: 1	Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 28465099]
CHO	EC₅₀	0.39 3 Compound: Pioglitazone	Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay Partial agonist activity at human PPARgamma expressed in CHO cells co-transfected with Gal4-responsive luciferase reporter plasmid after 24 hrs by transactivation assay	[PMID: 21377875]
HEK293	EC₅₀	1.1 3 Compound: 1	Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 28465099]
HEK293	IC₅₀	22 3 Compound: 1	Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay	[PMID: 28465099]
HEK293	EC₅₀	0.8 3 Compound: 4	Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay	[PMID: 23102891]
COS-1	EC₅₀	0.39 3 Compound: 2	Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay Agonist activity at human PPARgamma ligand binding domain expressed in COS-1 cells co-transfected with Gal4 by luciferase reporter gene assay	[PMID: 21130649]
HepG2	EC₅₀	0.57 3 Compound: Pioglitazone	Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay	[PMID: 22341573]
HEK293	IC₅₀	22 3 Compound: 1	Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay	[PMID: 28465099]
HT-1080	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
HepG2	EC₅₀	0.57 3 Compound: Pioglitazone	Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay	[PMID: 22341573]
COS-7	EC₅₀	0.2 3 Compound: Pioglitazone	Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay Transactivation of human PPARgamma expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay	[PMID: 26595749]
HT-1080	IC₅₀	>100 3 Compound: Pioglitazone	Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
MDA-MB-231	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
COS-7	EC₅₀	0.2 3 Compound: pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay	[PMID: 23130964]
HT-29	IC₅₀	40.3 3 Compound: Pioglitazone	Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
Mesenchymal stem cells	EC₅₀	0.5 3 Compound: Pio	Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay	[PMID: 37077388]
Mesenchymal stem cells	EC₅₀	0.79 3 Compound: PIO	Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA	[PMID: 36475432]
K562	GI₅₀	40.07 3 Compound: PG	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 32961322]
COS-7	EC₅₀	0.3 3 Compound: Pioglitazone	Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay Modulation of human PPARgamma-LBD expressed in african green monkey COS7 cells co-transfected with Gal4 assessed as activation of transactivation activity by luciferase assay	[PMID: 21873070]
Mesenchymal stem cells	EC₅₀	0.9 3 Compound: Pio	Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA	[PMID: 35859875]
K562	IC₅₀	0.29 3 Compound: Pioglitazone	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
COS-7	EC₅₀	0.3 3 Compound: pioglitazone	Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay Transactivation of human PPARgamma LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay	[PMID: 20307981]
MCF7	IC₅₀	0.07 3 Compound: Pioglitazone	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
COS-7	EC₅₀	0.32 3 Compound: Pioglitazone	Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay Transactivation at Gal4 fused PPARgamma LBD (unknown origin) expressed in African green monkey COS7 cells after 42 hrs by luciferase assay	[PMID: 27569195]
PC-3	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
MDA-MB-231	IC₅₀	>100 3 Compound: Pioglitazone	Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
COS-7	EC₅₀	0.5 3 Compound: Pioglitazone	Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay Transactivation of GAL4-fused human PPARgamma ligand binding domain expressed in African green monkey COS7 cells after 42 hrs by dual luciferase reporter gene assay	[PMID: 27560282]
THP-1	IC₅₀	> 50 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]
Mesenchymal stem cells	EC₅₀	0.79 3 Compound: PIO	Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA	[PMID: 36475432]
CV-1	EC₅₀	0.55 3 Compound: pioglitazone	Transactivation of PPARgamma in CV1 cells Transactivation of PPARgamma in CV1 cells	[PMID: 16821769]
THP-1	IC₅₀	18.6 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA	[PMID: 24531227]
Mesenchymal stem cells	EC₅₀	1.4 3 Compound: 41	Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin production in presence of IDX induction by Oil Red O staining based inverted microscopic analysis Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin production in presence of IDX induction by Oil Red O staining based inverted microscopic analysis	[PMID: 36967575]
CV-1	EC₅₀	0.69 3 Compound: 5	In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells In vitro transcriptional activation of Peroxisome proliferator activated receptor gamma (PPAR) expressed in CV-1 cells	[PMID: 8576907]
THP-1	IC₅₀	18.84 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]
Mesenchymal stem cells	EC₅₀	0.9 3 Compound: Pio	Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA	[PMID: 35859875]
THP-1	IC₅₀	2.97 2 Compound: Pioglitazone	Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation	[PMID: 30818268]
CV-1	EC₅₀	580 1 Compound: Pioglitazone	Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.	[PMID: 11720854]
Mesenchymal stem cells	EC₅₀	0.6 3 Compound: Pio	Induction of adiponectin biosynthesis in human BMMSC cells assessed as adiponectin level measured after 7 days by ELISA Induction of adiponectin biosynthesis in human BMMSC cells assessed as adiponectin level measured after 7 days by ELISA	[PMID: 36379105]
Mesenchymal stem cells	EC₅₀	0.5 3 Compound: Pio	Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay	[PMID: 37077388]
HEK293	EC₅₀	0.21 3 Compound: Pioglitazone	Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay Agonist activity at human PPARgamma expressed in HEK293 cells incubated for 18 hrs by luciferase reporter gene assay	[PMID: 25333853]
PC-3	IC₅₀	>100 3 Compound: Pioglitazone	Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
HEK293	EC₅₀	0.8 3 Compound: 4	Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay Transactivation of human GAL4-fused PPARgamma ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay	[PMID: 23102891]
CV-1	EC₅₀	580 1 Compound: Pioglitazone	Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay. Maximal reporter activity against human Peroxisome proliferator activated receptor gamma Gal4 chimeric in transiently transfected CV-1 cells by functional assay.	[PMID: 11720854]
HEK293	EC₅₀	1.1 3 Compound: 1	Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay Transactivation activity at Gal4 fused full length human PPARgamma LBD expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay	[PMID: 28465099]
Sf21	IC₅₀	0.3 3 Compound: Pioglitazone	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	2 3 Compound: Pioglitazone	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
HEK293	IC₅₀	22 3 Compound: 1	Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay Transrepression activity at human PPARgamma expressed in HEK293 cells assessed as inhibition of TNFalpha induced NF-kappaB promoter activity pretreated for 4 hrs followed by TNFalpha stimulation after 3 hrs by luciferase reporter gene assay	[PMID: 28465099]
THP-1	IC₅₀	>50 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]
THP-1	IC₅₀	18.6 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA	[PMID: 24531227]
THP-1	IC₅₀	18.84 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]
THP-1	IC₅₀	2.97 2 Compound: Pioglitazone	Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation	[PMID: 30818268]
HT-1080	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human HT1080 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
HT-29	IC₅₀	40.3 3 Compound: Pioglitazone	Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human HT-29 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
HepG2	EC₅₀	0.57 3 Compound: Pioglitazone	Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay Agonist activity at GAL4-tagged human PPARgamma ligand binding domain expressed in HepG2 cells assessed as transactivation after 20 hrs by beta-galactosidase reporter gene assay	[PMID: 22341573]
K562	GI₅₀	40.07 3 Compound: PG	Antiproliferative activity against human K562 cells assessed as cell growth inhibition Antiproliferative activity against human K562 cells assessed as cell growth inhibition	[PMID: 32961322]
K562	IC₅₀	0.29 3 Compound: Pioglitazone	Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human K562 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
MCF7	IC₅₀	0.07 3 Compound: Pioglitazone	Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay Anticancer activity against human MCF7 cells assessed as cell growth inhibition measured after 48 hrs by MTT assay	[PMID: 36481599]
MDA-MB-231	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
Mesenchymal stem cells	EC₅₀	0.5 3 Compound: Pio	Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay Induction of adiponectin secretion in human BMMSC cells in presence of IDX induction medium by ELISA assay	[PMID: 37077388]
Mesenchymal stem cells	EC₅₀	0.6 3 Compound: Pio	Induction of adiponectin biosynthesis in human BMMSC cells assessed as adiponectin level measured after 7 days by ELISA Induction of adiponectin biosynthesis in human BMMSC cells assessed as adiponectin level measured after 7 days by ELISA	[PMID: 36379105]
Mesenchymal stem cells	EC₅₀	0.79 3 Compound: PIO	Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA Induction of adipogenesis in differentiated human BMMSC cells assessed as fold increase in adiponectin level in presence of IDX by ELISA	[PMID: 36475432]
Mesenchymal stem cells	EC₅₀	0.9 3 Compound: Pio	Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin secretion and measured on 5 day in presence of IDX induction medium by ELISA	[PMID: 35859875]
Mesenchymal stem cells	EC₅₀	1.4 3 Compound: 41	Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin production in presence of IDX induction by Oil Red O staining based inverted microscopic analysis Induction of adipogenesis in human differentiated BMMSC cells assessed as increase in adiponectin production in presence of IDX induction by Oil Red O staining based inverted microscopic analysis	[PMID: 36967575]
PC-3	IC₅₀	> 100 3 Compound: Pioglitazone	Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxic activity in human PC3 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 28395220]
Sf21	IC₅₀	0.3 3 Compound: Pioglitazone	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	2 3 Compound: Pioglitazone	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
THP-1	IC₅₀	18.6 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion incubated for 2 hrs prior to PMA challenge measured after 72 hrs by ELISA	[PMID: 24531227]
THP-1	IC₅₀	18.84 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced MCP-1 secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]
THP-1	IC₅₀	2.97 2 Compound: Pioglitazone	Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation Inhibition of PMA-induced human THP1 monocytes differentiation in to macrophages assessed as macrophage metabolic activity preincubated for 6 hrs before PMA stimulation	[PMID: 30818268]
THP-1	IC₅₀	> 50 3 Compound: Pioglitazone	Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA Antiinflammatory activity in human THP1 cells assessed as inhibition of PMA-induced IL-1beta secretion preincubated for 1 hr prior PMA-challenge measured after 48 hrs by ELISA	[PMID: 23811092]

In Vitro

Pioglitazone (0.5 or 1 μM, 5 days) can completely prevent AGEs (advanced glycation end-products)-induced β-cell necrosis and the increase of caspase-3 thereby avoiding the impaired viability caused by AGEs in pancreatic beta cell line HIT-T15^[2].
Pioglitazone (1 μM, 1 h) can stimulate insulin secretion induced by low glucose concentration and attenuate the GSSG/GSH ratio in cells cultured with AGEs^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle^[3].
Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	ob/ob and adipo^-/- ob/ob mice with a C57Bl/6 background^[3]
Dosage:	10 or 30 mg/kg
Administration:	Oral gavage; once daily; 14 days
Result:	Showed no changes of serum-free fatty acid and triglyceride levels as well as adipocyte sizes in ob/ob and adipo^-/- ob/ob C57BL/6 mice at 10 mg/kg but significantly reduced to a similar degree at 30 mg/kg. Also showed no changes of expressions of TNFα and resistin in adipose tissues of ob/ob and adipo^-/- ob/ob mice at 10 mg/kg but decreased at 30 mg/kg.

Animal Model:	Male Wistar albino rats^[4]
Dosage:	10 mg/kg
Administration:	Oral gavage; once daily; 4 weeks
Result:	Decreased the elevated serum levels of both creatinine and creatine kinase-MB (CK-MB), TGF-β1 gene expression and regulated the expression of MMP-2/TIMP-2 system.

Clinical Trial

Molecular Weight

356.44

Formula

C₁₉H₂₀N₂O₃S

CAS No.

111025-46-8

Appearance

Solid

Color

White to off-white

SMILES

O=C(N1)SC(CC2=CC=C(OCCC3=NC=C(CC)C=C3)C=C2)C1=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 25 mg/mL (70.14 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8055 mL	14.0276 mL	28.0552 mL
5 mM	0.5611 mL	2.8055 mL	5.6110 mL
10 mM	0.2806 mL	1.4028 mL	2.8055 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (5.84 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.84 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (28.06 mM); Suspened solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.70%

Select Batch:

Data Sheet (278 KB) SDS (419 KB)

COA (246 KB) HNMR (266 KB) RP-HPLC (210 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve [Content Brief]

[2]. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. [Content Brief]

[3]. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. [Content Brief]

[4]. Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8055 mL	14.0276 mL	28.0552 mL	70.1380 mL
	5 mM	0.5611 mL	2.8055 mL	5.6110 mL	14.0276 mL
	10 mM	0.2806 mL	1.4028 mL	2.8055 mL	7.0138 mL
	15 mM	0.1870 mL	0.9352 mL	1.8703 mL	4.6759 mL
	20 mM	0.1403 mL	0.7014 mL	1.4028 mL	3.5069 mL
	25 mM	0.1122 mL	0.5611 mL	1.1222 mL	2.8055 mL
	30 mM	0.0935 mL	0.4676 mL	0.9352 mL	2.3379 mL
	40 mM	0.0701 mL	0.3507 mL	0.7014 mL	1.7535 mL
	50 mM	0.0561 mL	0.2806 mL	0.5611 mL	1.4028 mL
	60 mM	0.0468 mL	0.2338 mL	0.4676 mL	1.1690 mL

Pioglitazone Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Pioglitazone111025-46-8U 72107U72107U-72107PPARFerroptosisPeroxisome proliferator-activated receptorsPPARγligand-bindingdomainblood glucosediabeteInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Pioglitazone (Synonyms: U 72107)

Customer Review

Other Forms of Pioglitazone:

Pioglitazone Related Antibodies

47 Publications Citing Use of MCE Pioglitazone

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Pioglitazone Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Pioglitazone Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report